Boston Scientific plunges 43% YTD amid weak outlook but shows potential for recovery with new Buy rating.

Boston Scientific's stock has dropped over 43% year-to-date, wiping out years of gains due to lowered guidance and weakness in key segments like WATCHMAN and Urology. Despite this, a new Buy rating has been initiated, citing achievable guidance after a Q1 reset and expected easing of sales comparisons in the second half of the year that could stabilize the stock. Key risks remain, including further guidance cuts and macroeconomic factors slowing procedures. The stock trades in line with peers, and consistent execution with reaffirmed guidance could drive a recovery.